Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Verapamil in angina pectoris.

D T Kelly

    British Journal of Clinical Pharmacology
    |January 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Verapamil, a calcium antagonist, effectively treats angina pectoris by dilating coronary arteries and improving cardiac output. It offers a safe, long-term therapeutic option with few side effects for stable angina patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Endothelial dysfunction: therapy revisited (brief excerpts) (round table discussion on 18/01/2001 at Mumbai).

    Journal of the Indian Medical Association·2001
    Same author

    Disease burden of cardiovascular disease in the elderly.

    Coronary artery disease·1998
    Same author

    Paul Dudley White International Lecture. Our future society. A global challenge.

    Circulation·1997
    Same author

    Beta-blocker therapy in heart failure: myths or realities.

    Journal of cardiac failure·1996
    Same author

    Intermittent transdermal nitrates do not improve ischemia in patients taking beta-blockers or calcium antagonists: potential role of rebound ischemia during the nitrate-free period.

    Journal of the American College of Cardiology·1995
    Same author

    Vascular effects of diuretics in heart failure.

    British heart journal·1994
    Same journal

    UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).

    British journal of clinical pharmacology·2026
    Same journal

    Comparative risk of ventricular arrhythmia and sudden cardiac death among acetylcholinesterase inhibitors in dementia: A population-based cohort study.

    British journal of clinical pharmacology·2026
    Same journal

    Population pharmacokinetics and pharmacodynamics of canagliflozin in paediatric patients with type 2 diabetes mellitus.

    British journal of clinical pharmacology·2026
    Same journal

    Impact of cumulative glucocorticoid exposure on vancomycin clearance in hospitalized children: A retrospective cohort study.

    British journal of clinical pharmacology·2026
    Same journal

    Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs.

    British journal of clinical pharmacology·2026
    Same journal

    Case-malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy.

    British journal of clinical pharmacology·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Coronary artery disease pathophysiology has advanced therapeutic strategies for angina pectoris.
    • Calcium antagonists offer direct coronary vasodilation and reduce cardiac demand via systemic vasodilation.

    Purpose of the Study:

    • To evaluate verapamil as an initial therapy for stable angina pectoris.
    • To compare the efficacy and side-effect profile of verapamil with beta-adrenoceptor blockers.

    Main Methods:

    • Clinical assessment of anti-anginal effects during exercise.
    • Evaluation of cardiac output and patient-reported fatigue.
    • Long-term monitoring of side-effect incidence and therapeutic tolerance.

    Main Results:

    • Verapamil demonstrated equivalent anti-anginal effects to beta-blockers during exercise.

    Related Experiment Videos

  • Unlike beta-blockers, verapamil increased cardiac output and did not induce fatigue.
  • Few long-term side effects were recorded, with no tolerance observed over a 5-year period.

    • Conclusions:

    • Verapamil is a well-tolerated, effective single-agent therapy for stable angina pectoris.
    • Its ability to improve cardiac output makes it advantageous over beta-blockers.
    • Verapamil should be considered for initial treatment of stable angina pectoris.